Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Craig Venter, Ted Goldstein, Jeffrey Busch, John Brugmann, Mick Ruxin, More

Craig Venter

Craig Venter announced that he is retiring from Human Longevity, the company he cofounded and where he serves as chairman and CEO. Venter said in a tweet that he will be returning to the J. Craig Venter Institute, which he founded in 2006, "to continue my work."

Ted Goldstein

Precision medicine informatics company GNS Healthcare has named bioinformatician and biomedical engineer Ted Goldstein to its strategic advisory board. Goldstein, who serves as the scientific program director of computational health at the University of California, San Francisco, is leading the development of a machine learning-based comprehensive cancer diagnosis and treatment model for the university. He previously served as vice president of developer tools at Apple and as an e-commerce hardware developer for Sun Microsystems.

Jeffrey Busch, John Brugmann, Mick Ruxin

Avant Diagnostics has appointed Jeffrey Busch as chairman of its board of directors and John Brugmann as a director on the board. In addition, Mick Ruxin has joined the firm as CEO, resident, and board member.

For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.